Predictors of urinary morbidity in Cs-131 prostate brachytherapy implants

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 3, 2011, Pages 745-750

  Smith, Ryan P ^a   Jones, Heather A ^a   Beriwal, Sushil ^a   Gokhale, Abhay ^a   Benoit, Ronald ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Cesium; Prostate cancer; Toxicity

Indexed keywords

BLADDER NECK; BRACHYTHERAPY; EXPANDED PROSTATE CANCER INDEX COMPOSITES; EXTERNAL BEAM RADIATION THERAPY; MULTI VARIATE ANALYSIS; PROSTATE BRACHYTHERAPY; PROSTATE CANCERS; TIME POINTS; URINARY FUNCTIONS; URINARY MORBIDITY;

DISEASES; DOSIMETRY; MULTIVARIANT ANALYSIS; ONCOLOGY; RADIOTHERAPY; REGRESSION ANALYSIS; TOXICITY;

CESIUM;

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CESIUM 131;

ADULT; AGED; ARTICLE; BLADDER CATHETERIZATION; BRACHYTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COHORT ANALYSIS; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE ANALYSIS OF COVARIANCE; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BRACHYTHERAPY; PROSTATE CANCER; URINARY TRACT FUNCTION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRACHYTHERAPY; CESIUM RADIOISOTOPES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TIME FACTORS; URINARY BLADDER; URINARY CATHETERIZATION; URINATION DISORDERS;

EID: 79956208938     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.06.017     Document Type: Article

References (33)

1. P.D. Grimm, J.C. Blasko, and J.E. Sylvester 10-year biochemical (prostate-specific antigen) control of prostate cancer with I-125 brachytherapy Int J Radiat Oncol Biol Phys 51 2001 31 40 (Pubitemid 32758858)
2. M.A. Kollmeier, R.G. Stock, and N. Stone Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality Int J Radiat Oncol Biol Phys 57 2003 645 653 (Pubitemid 37194290)
3. L. Potters, C. Morgenstern, and E. Calugaru 12-year outcomes following permanent prostate brachytherapy in patients with classically localized prostate cancer J Urol 173 2005 1562 1566 (Pubitemid 40524771)
4. J.F. Anderson, D.A. Swanson, L.B. Levy, D.A. Kuban, A.K. Lee, R. Kudchadker, J. Phan, T. Bruno, and S.J. Frank Urinary side effects and complications after permanent prostate brachytherapy: The M.D. Anderson Cancer Center experience Urology 74 2009 601 605
5. M. Keyes, S. Miller, and S. Moravan Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients Int J Radiat Oncol Biol Phys 73 2009 1023 1032
6. M.P. Van Gellekom, M.A. Moerland, and M. Van Vulpen Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry Int J Radiat Oncol Biol Phys 63 2005 772 780 (Pubitemid 41400065)
7. J.A. Talcott, J. Manol, and J.A. Clark Time course and predictors of symptoms after primary prostate cancer therapy J Clin Oncol 21 2003 3979 3986 (Pubitemid 46606212)
8. Jacobs BL, Smith RP, Beriwal S, Benoit RM. Acute lower urinary tract symptoms after prostate brachytherapy with Cesium-131. Urology. Urology 2010, June 3 [epub ahead of print].
9. J.T. Wei, R.L. Dunn, and M.S. Litwin Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer Urology 56 2000 899 905
10. IsoRay Medical Inc. CS-131 product information sheet. Available at: http://www.isoray.com/.
11. Kinsey RR. The NuDat program for nuclear data on the web. National Nuclear Data Center, Brookhaven National Laboratory. Available at: http://www.nndc.bnl.gov/nndc/nudat/.
12. R. Nath, L.L. Anderson, G. Luxton, K.A. Weaver, J.F. Williamson, and A.S. Meigooni Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 Med Phys 22 1995 209
13. J.A. Talcott, P. Rieker, and J.A. Clark Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study J Clin Oncol 16 1998 275 283 (Pubitemid 28041609)
14. G.S. Merrick, W.M. Butler, J.H. Lief, and A.T. Dorsey Temporal resolution of urinary morbidity following prostate brachytherapy Int J Radiat Oncol Biol Phys 47 2000 121 128 (Pubitemid 30179685)
15. M. Neill, G. Studer, and L.N. Lee The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry Brachytherapy 6 2007 173 179 (Pubitemid 47187799)
16. N.N. Stone, and R.G. Stock Long-term urinary, sexual, and rectal morbidity in patients treated with I-125 prostate brachytherapy followed up for a minimum of 5 years Urology 69 2007 338 342 (Pubitemid 46274929)
17. J. Crook, N. Fleshner, C. Roberts, and G. Pond Long-term urinary sequelae following 125iodine prostate brachytherapy J Urol 179 2008 141 145
18. A. Niehaus, G.S. Merrick, and W.M. Butler The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy Int J Radiat Oncol Biol Phys 64 2006 136 143 (Pubitemid 41831220)
19. Z.A. Allen, G.S. Merrick, and W.M. Butler Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity Int J Radiat Oncol Biol Phys 62 2005 981 987 (Pubitemid 40884407)
20. K. Kelly, R. Swindell, and J. Routledge Prediction of urinary symptoms after 125iodine prostate brachytherapy Clin Oncol (R Coll Radiol) 18 2006 326 332
21. D. Brown, A. Colonias, and R. Miller Urinary morbidity with a modified peripheral loading technique of transperineal (125)I prostate implantation Int J Radiat Oncol Biol Phys 47 2000 353 360 (Pubitemid 30236375)
22. K. Wallner, J. Roy, and L. Harrison Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy Int J Radiat Oncol Biol Phys 32 1995 465 471
23. G.S. Merrick, W.M. Butler, and K.E. Wallner Long-term urinary quality of life following permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 56 2003 454 461 (Pubitemid 36542903)
24. M.G. Sanda, R.L. Dunn, and J. Michalski Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 358 2008 1250 1261 (Pubitemid 351439226)
25. R.G. Stock, A. Ho, J.A. Cesaretti, and N.N. Stone Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control Int J Radiat Oncol Biol Phys 66 2006 389 394 (Pubitemid 44332760)
26. H. Ragde, L.J. Korb, and A.A. Elgamal Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up Cancer 89 2000 135 141 (Pubitemid 30451283)
27. S.J. Frank, P.D. Grimm, and J.E. Sylvester Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States Brachytherapy 6 2007 2 8 (Pubitemid 46187329)
28. D.Y. Gelblum, L. Potters, and R. Ashley Urinary morbidity following ultrasound-guided transperineal prostate seed implantation Int J Radiat Oncol Biol Phys 45 1999 59 67 (Pubitemid 29380075)
29. A. Henderson, S.R. Bott, and P. Sooriakumaran Urinary morbidity after 125I brachytherapy of the prostate BJU Int 93 2004 890 (Pubitemid 38497056)
30. J. Locke, W. Ellis, K. Wallner, W. Cavanagh, and J. Blasko Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study Int J Radiat Oncol Biol Phys 52 2002 712
31. M.D. Terk, R.G. Stock, and N.N. Stone Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate J Urol 160 1998 1379 1382 (Pubitemid 29480520)
32. C. Thomas, M. Keyes, and M. Liu Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms prior to permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 72 2008 447 455
33. R.C. Chen, J.A. Clark, and J.A. Talcott Individualizing quality-of-life outcomes reporting: How localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function J Clin Oncol 27 24 2009 Aug 20 3916 3922